Routine antenatal anti-D prophylaxis for women who are rhesus D negative

The Committee was aware that a test is currently being developed that determines fetal blood type by genotyping of fetal DNA present in the maternal circulation.

Head-to-head trials of single-dose versus two-dose RAADP regimens are required to establish relative efficacy.

A study to better estimate the disutility of fetal and neonatal loss, as well as the disutility to parents who experience such a loss, is required.